Skip to content

Libor Uttl

5 papers in the library · 134 citations · publishing 2017-2026

Papers

Sort Most recent Most cited

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats.

Pharmacology, Biochemistry, and Behavior June 30, 2026 Lucie Ladislavová, Viera Kútna, Kristýna Mazochová et al.

Psilocin (4-hydroxy-N, N-dimethyltryptamine) is a substituted tryptamine alkaloid and a nonselective serotonergic agonist acting predominantly at 5-HT2A/C receptors, with substantial binding to 5-HT1A and 5-HT2B receptors. Microdosing is the practice of taking a very small, sub-perceptual dose, typically 5% to 10% of a full recreational dose, to improve mood, creativity, and focus without...

Behavioral and Pharmacokinetic Profile of Indole-Derived Synthetic Cannabinoids JWH-073 and JWH-210 as Compared to the Phytocannabinoid Δ9-THC in Rats

Frontiers in Neuroscience October 23, 2018 Libor Uttl, Ewa Szczurowska, Kateřina Hájková et al. 24 citations

Synthetic cannabinoid compounds are marketed as ‘legal’ marijuana substitutes, even though little is known about their behavioral effects in relation to their pharmacokinetic profiles. Therefore, in the present study we investigated the behavioral effects of systemic treatment with the two synthetic cannabinoids JWH-073 and JWH-210 and the phytocannabinoid Δ9-THC on locomotor activity and...

Mephedrone (4-Methylmethcathinone): Acute Behavioral Effects, Hyperthermic, and Pharmacokinetic Profile in Rats

Frontiers in Psychiatry January 10, 2018 Klára Šíchová, Nikola Pinterová, Monika Židková et al. 28 citations

Mephedrone (MEPH) is a synthetic cathinone derivative with effects that mimic MDMA and/or cocaine. Our study in male Wistar rats provides detailed investigations of MEPH's and its primary metabolite nor-mephedrone's (nor-MEPH) pharmacokinetics and bio-distribution to four different substrates (serum, brain, lungs, and liver), as well as comparative analysis of their effects on locomotion [open...

DOI: 10.3389/fpsyt.2017.00306 (opens in new tab) Pharmacology Mephedrone Pharmacokinetics Drug

Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.

European Neuropsychopharmacology December 2017 Tomáš Hložek, Libor Uttl, Lukáš Kadeřábek et al.

Metabolic and behavioural effects of, and interactions between Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are influenced by dose and administration route. Therefore we investigated, in Wistar rats, effects of pulmonary, oral and subcutaneous (sc.) THC, CBD and THC+CBD. Concentrations of THC, its metabolites 11-OH-THC and THC-COOH, and CBD in serum and brain were determined over 24h,...

DOI: 10.1016/j.euroneuro.2017.10.037 (opens in new tab) Full text (opens in new tab) Behaviour Cannabidiol CBD Pharmacokinetics δ9-Tetrahydrocannabinol THC

Pharmacokinetic, Ambulatory, and Hyperthermic Effects of 3,4-Methylenedioxy-N-Methylcathinone (Methylone) in Rats

Frontiers in Psychiatry November 17, 2017 Kristýna Štefková, Monika Židková, Rachel R. Horsley et al. 82 citations

-methylcathinone) is a synthetic cathinone analog of the recreational drug ecstasy. Although it is marketed to recreational users as relatively safe, fatalities due to hyperthermia, serotonin syndrome, and multi-organ system failure have been reported. Since psychopharmacological data remain scarce, we have focused our research on pharmacokinetics, and on a detailed evaluation of temporal...

DOI: 10.3389/fpsyt.2017.00232 (opens in new tab) Pharmacology Cathinone Mephedrone Pharmacokinetics +3